On Tuesday, Shares of Gilead Sciences, Inc. (NASDAQ:GILD), gained 1.27% to $96.00.
Gilead Sciences declared topline results from four international Phase 3 clinical studies (ASTRAL-1, ASTRAL-2, ASTRAL-3 and ASTRAL-4) evaluating a once-daily, fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF) with velpatasvir (VEL), an investigational pangenotypic NS5A inhibitor, for the treatment of genotype 1-6 chronic hepatitis C virus (HCV) infection.
In the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies, 1,035 patients with genotype 1-6 HCV infection received 12 weeks of SOF/VEL. Among these patients, 21 percent had compensated cirrhosis and 28 percent had failed prior treatments. The ASTRAL-4 study randomized 267 patients with decompensated cirrhosis (Child-Pugh class B) to receive 12 weeks of SOF/VEL with or without ribavirin (RBV), or 24 weeks of SOF/VEL. The primary endpoint for all studies was SVR12.
Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions.
Shares of Xerox Corp (NYSE:XRX), declined -1.56% to $9.49, during its last trading session.
To help businesses and government better secure products as they are distributed, Xerox (XRX) recently introduced two printed electronic labels (also known as “printed memory”) that can collect and store information about the authenticity and condition of products.
Xerox Printed Memory is a highly secure, printed label containing up to 36 bits of rewritable memory which can store up to 68 billion points of data. The labels, for example, can be used to determine if a product is genuine and to track how it’s been handled during distribution.
The second product, Xerox Printed Memory with Cryptographic Security comprises a unique, encrypted printed code (such as a QR bar code) to the memory. It can only be read by authorized personnel using a reader which interfaces with a secure smartphone application. This combination of printed memory with an encrypted printed code, creates one of the most secure anti-counterfeit solutions on the market. It is ideal for use in applications as wide ranging as tracking and ensuring the safety of pharmaceutical products to securing tax or duty stamps for government agencies. The cryptographic security feature was developed at PARC, A Xerox company, and is an added feature in the printed memory labels.
Xerox Corporation is engaged in offering business process and document management solutions. The Company operates through the following segments: Services, Document Technology and Other. The Company’s customers include small and midsize businesses (SMBs), graphic communications companies, Governmental entities, educational institutions and Fortune 1000 corporate accounts.
Shares of JD.Com Inc (ADR) (NASDAQ:JD), declined -1.05% to $24.43, during its last trading session.
JD.Com Inc, declared the launch of Italian Fashion Mall, a new platform on JD.com dedicated to introducing Italian fashion brands and products to consumers in China. JD.com and Europe Design Center also recently jointly declared the participation of three renowned Chinese fashion designers — Lin Gu, Ali Tan and Xiaoyan Xu — in Milan Fashion Week. The three designers were selected through a competitive program run by JD.com and Europe Design Center, and their participation marks the first time Chinese designers will take part in Milan Fashion Week.
The declaration was made at an event during the Milan Fashion Week and was attended by Honorary President of Camera Nazionale della Moda Italiana and Europe Design Center, Mario Boselli; Vice President of JD.com and President of JD Mall’s Apparel and Home Furnishing Business Unit, Lijun Xin; and over 50 guests from the Italian fashion industry.
In addition to bringing top Italian fashion brands to China, JD.com is dedicated to introducing outstanding Chinese fashion talent and brands to the international stage. In August 2015, JD.com and Europe Design Center jointly launched a competitive fashion program to support Chinese designers. Three candidates were selected to take part in Milan Fashion Week through a rigorous process involving assessment by fashion experts in addition to online voting by consumers. Each of the designers’ labels has been recognized as a brand with the potential to succeed internationally.
JD.com, Inc. is an online direct sales company. The Company engages primarily in the sale of electronics and home appliance products and general merchandise products (including audio, video products and books) sourced from manufacturers, distributors and publishers in People’s republic of China (PRC) on the Internet through its Website jd.com.
Finally, Mallinckrodt PLC (NYSE:MNK), ended its last trade with -3.08% loss, and closed at $57.96.
Mallinckrodt declared that it has accomplished its acquisition of Therakos, Inc., from The Gores Group at a purchase price of about $1.325 billion. The Therakos acquisition further broadens Mallinckrodt’s footprint in hospitals – expanding its reach into immunotherapy through extracorporeal photopheresis (ECP) and extending the company’s presence from multimodal surgical pain administration and critical care respiratory therapies in neonatal intensive care units to comprise innovative therapies that harness the patient’s own immune systems to fight disease and improve health.
The all-cash transaction is predictable to be accretive by no less than $0.10 per share to Mallinckrodt’s adjusted diluted fiscal 2016 earnings and increasingly accretive thereafter. The company anticipates fiscal 2015 net sales for Therakos products of $185 million to $195 million, and anticipates high single-digit growth off that base going forward.
Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
